IL6 and breast carcinoma: Additionally, the RNA-seq data analysis on transcriptomic changes due to miR-662 overexpression in BC cells revealed that HMGA2 and IL6R, which both directly contribute to breast cancer stemness properties [53–55], and the transcription factor C/EBPδ, which acts upstream of IL-6 signalling through activation of IL6R [56], were upregulated in miR-662-overexpressing MDA-MB-231 cells compared to controls (Fig. 6a).